Article
Distinctive activation patterns in constitutively active and gefitinib-sensitive EGFR mutants.
Oncogene - 23 Feb 2006
Chen Y-R, Fu Y-N, Lin C-H, Yang S-T, Hu S-F, Chen Y-T, Tsai S-F, Huang S-F
Abstract excerpt
Mutations in the kinase domain of epidermal growth factor receptor (EGFR) are associated with clinical responsiveness to gefitinib in patients with non-small-cell lung cancers (NSCLC). Recently, we have identified many novel EGFR mutations in NSCLC tissues. In this study, we found that gefitinib...
Topics
- Animals
- Antineoplastic Agents
- COS Cells
- Carcinoma, Non-Small-Cell Lung
- Chlorocebus aethiops
- Epidermal Growth Factor
- ErbB Receptors
- Gefitinib
- Immunoprecipitation
- Lung Neoplasms
- Mutation
- Phosphorylation
- Quinazolines
- Tumor Cells, Cultured
- Tyrosine
- Ubiquitin